DelveInsight has launched a new report on “Trigeminal Neuralgia – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Trigeminal Neuralgia Market Report:
- As per an organization, trigeminal neuralgia affects females slightly more often than males. Although the exact incidence is unknown, approximately 10,000–15,000 new cases occur each year in the United States.
- A study indicated that the incidence of trigeminal neuralgia (TN) is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9 per 100,000) as compared to men (3.4 per 100,000). There is a lack of certainty regarding the etiology and pathophysiology of TN.
- A study stated that trigeminal neuralgia (TN) has an incidence ranging from about 4–5 per 100,000 per year up to 20 per 100,000 per year after age 60. The female-to-male ratio is about 3:2.
Key benefits of the report:
- Trigeminal Neuralgia market report covers a descriptive overview and comprehensive insight of the Trigeminal Neuralgia Epidemiology and Trigeminal Neuralgia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Trigeminal Neuralgia market report provides insights on the current and emerging therapies.
- Trigeminal Neuralgia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Trigeminal Neuralgia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Trigeminal Neuralgia market.
Got queries? Click here to know more about the Trigeminal Neuralgia Market Landscape
Trigeminal Neuralgia Overview
Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. It is a form of neuropathic pain (pain associated with nerve injury or nerve lesion) and is categorized into two types: primary (idiopathic) and secondary.
Trigeminal Neuralgia Market
The dynamics of the Trigeminal Neuralgia market is anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Biogen, Biohaven Pharmaceuticals, and others during the forecasted period 2019-2032.
Trigeminal Neuralgia Pipeline Therapies and Key Companies
- Vixotrigine (BIIB074): Biogen
- Rimegepant: Biohaven Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Trigeminal Neuralgia Patient Share (%) Overview at a Glance
5. Trigeminal Neuralgia Market Overview at a Glance
6. Trigeminal Neuralgia Disease Background and Overview
7. Trigeminal Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Trigeminal Neuralgia
9. Trigeminal Neuralgia Current Treatment and Medical Practices
10. Unmet Needs
11. Trigeminal Neuralgia Emerging Therapies
12. Trigeminal Neuralgia Market Outlook
13. Country-Wise Trigeminal Neuralgia Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Trigeminal Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Trigeminal Neuralgia Market Outlook 2032
Related Reports:
Trigeminal Neuralgia Pipeline
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/